8.805

1.29% -0.115

After Hours: 8.77 -0.035 -0.40%

Emergent Biosolutions Inc (EBS)

Overview News Price History Option Chain Discussions Forecast

Emergent Biosolutions Inc stock is traded at $8.805, with a volume of 1.57M. It is down -1.29% in the last 24 hours and down -22.83% over the past month. Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Previous Close:

$8.92

Open:

$8.9

24h Volume:

1.57M

Relative Volume:

1.72

Market Cap:

$460.07M

Revenue:

$1.02B

Net Income/Loss:

$-757.20M

P/E Ratio:

-0.5965

EPS:

-14.76

Net Cash Flow:

$-257.90M

1W Performance:

-20.03%

1M Performance:

-22.83%

6M Performance:

+15.40%

1Y Performance:

+37.79%

1-Day Range:

$8.665

$9.025

1-Week Range:

$7.81

$11.46

52-Week Range:

$4.02

$14.06

Emergent Biosolutions Inc Stock (EBS) Company Profile

Name

Emergent Biosolutions Inc

Sector

Healthcare (1113)

Industry

Drug Manufacturers - Specialty & Generic (83)

Phone

240-631-3200

Address

300 PROFESSIONAL DR, GAITHERSBURG, MD

Employee

900

Twitter

@emergentbiosolu

Next Earnings Date

2025-03-03

Latest SEC Filings

EBS's Discussions on Twitter

Compare EBS vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EBS Emergent Biosolutions Inc	8.76	468.48M	1.02B	-757.20M	-257.90M	-14.76
TAK Takeda Pharmaceutical Co Adr	18.22	57.12B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	125.98	53.16B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.48	47.25B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	32.88	37.59B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	490.21	21.85B	3.13B	1.27B	1.12B	26.39

Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-30-24	Initiated	H.C. Wainwright	Buy
Aug-22-24	Initiated	Rodman & Renshaw	Buy
Mar-07-24	Upgrade	The Benchmark Company	Hold → Buy
Nov-20-23	Resumed	JP Morgan	Underweight
Aug-29-23	Downgrade	The Benchmark Company	Buy → Hold
Apr-10-23	Upgrade	The Benchmark Company	Hold → Buy
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-10-22	Downgrade	The Benchmark Company	Buy → Hold
Apr-29-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-20-22	Upgrade	The Benchmark Company	Hold → Buy
Nov-08-21	Downgrade	The Benchmark Company	Buy → Hold
May-05-21	Downgrade	Argus	Buy → Hold
Apr-07-21	Initiated	The Benchmark Company	Buy
Feb-24-21	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-19-21	Downgrade	Chardan Capital Markets	Buy → Neutral
Jan-08-21	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-14-20	Resumed	JP Morgan	Neutral
Jul-31-20	Reiterated	Chardan Capital Markets	Buy
Sep-12-19	Initiated	Guggenheim	Buy
Sep-04-19	Upgrade	Wells Fargo	Market Perform → Outperform
Nov-02-18	Upgrade	Goldman	Neutral → Buy
Aug-03-18	Reiterated	Chardan Capital Markets	Buy
Jun-13-18	Initiated	Argus	Buy
Apr-25-18	Downgrade	Wells Fargo	Outperform → Market Perform
Jan-24-18	Initiated	Goldman	Neutral
Jan-16-18	Reiterated	Chardan Capital Markets	Buy
Jun-28-16	Reiterated	Singular Research	Buy
Apr-15-16	Initiated	Chardan Capital Markets	Buy
Mar-28-16	Initiated	Singular Research	Buy
Feb-19-16	Initiated	Wells Fargo	Outperform
May-15-14	Initiated	Summer Street Research	Buy
May-31-11	Reiterated	WBB Securities	Strong Buy
Jan-10-11	Reiterated	Wedbush	Outperform
Nov-05-10	Reiterated	Wedbush	Outperform
Aug-18-10	Upgrade	WBB Securities	Buy → Strong Buy
Aug-06-10	Reiterated	Caris & Company	Buy

View All

Emergent Biosolutions Inc Stock (EBS) Latest News

Mar 03, 2026

EBS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 03, 2026

Emergent BioSolutions (EBS) SVP reports 116-share tax-withholding disposition - Stock Titan

Mar 03, 2026

Emergent BioSolutions (EBS) CFO logs 683-share tax-withholding disposition - Stock Titan

Mar 03, 2026

Emergent BioSolutions (EBS) EVP has 313 shares withheld for RSU taxes - Stock Titan

Mar 03, 2026

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors - The Globe and Mail

Mar 03, 2026

Emergent BioSolutions announces appointment of John D. Fowler, Jr. to board of directors - marketscreener.com

Mar 03, 2026

Emergent BioSolutions Adds Independent Director Amid Turnaround Efforts - TipRanks

Mar 03, 2026

Emergent BioSolutions appoints John D. Fowler, Jr. as director and Audit and Finance Committee member - TradingView

Mar 03, 2026

John Fowler joins Emergent BioSolutions (NYSE: EBS) board, Audit role - Stock Titan

Mar 03, 2026

Emergent Biosolutions Announces Appointment Of John D. Fowler, Jr. To Board Of Directors - TradingView

Mar 03, 2026

Former Wells Fargo banker John Fowler joins Emergent BioSolutions board - Stock Titan

Mar 03, 2026

Mar 02, 2026

Emergent Biosolutions secures new contracts with Public Health Agency of Canada and Defence Department - Traders Union

Mar 02, 2026

Mar 01, 2026

Aug Levels: Is Emergent BioSolutions Inc stock showing strong momentumPortfolio Performance Summary & Accurate Intraday Trading Signals - baoquankhu1.vn

Mar 01, 2026

Feb 28, 2026

Q4 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus

Feb 28, 2026

Emergent BioSolutions Earnings: Revenue, Margins And GAAP Losses Paint Mixed Picture (EBS) - Seeking Alpha

Feb 28, 2026

Emergent BioSolutions (EBS) Stock Falls on Disappointing Revenue Guidance - GuruFocus

Feb 27, 2026

Emergent BioSolutions authorizes $50M stock buyback program By Investing.com - Investing.com India

Feb 27, 2026

Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today? - Stocktwits

Feb 27, 2026